Royalty Pharma plc Class A Ordinary Shares $57.66BIIB · NASDAQ-GS
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $9.89B | $9.68B | $9.84B | $10.17B | $10.98B | $13.44B | $14.38B | $13.45B |
| Cost of Revenue | $2.40B | $2.31B | $2.53B | $2.28B | $2.11B | $1.81B | $1.96B | $1.82B |
| Gross Profit | — | — | — | — | — | $11.64B | $12.42B | $11.64B |
| Selling, General & Administrative | $2.43B | $2.40B | $2.55B | $2.40B | $2.67B | $2.50B | $2.37B | $2.11B |
| Operating Expenses | $8.33B | $7.77B | $8.54B | $6.58B | $9.24B | $8.40B | $7.34B | $7.56B |
| Operating Income | — | — | — | — | $2.84B | $4.55B | $7.04B | $5.89B |
| Interest Expense | $267.50M | $250.30M | $246.90M | $246.60M | $253.60M | $222.50M | $187.40M | $200.60M |
| Other Income / (Expense) | -$305.60M | -$343.60M | -$315.50M | $108.20M | -$1.10B | $497.40M | $83.30M | $11.00M |
| Income Before Taxes | $1.56B | $1.91B | $1.30B | $3.59B | $1.75B | $5.05B | $7.13B | $5.90B |
| Provision for Income Taxes | $263.60M | $273.80M | $135.30M | $632.80M | $52.50M | $992.30M | $1.16B | $1.43B |
| Net Income | $1.29B | $1.63B | $1.16B | $3.05B | $1.56B | $4.00B | $5.89B | $4.43B |
| Basic EPS | $8.83 | $11.21 | $8.02 | $20.96 | $10.44 | $24.86 | $31.47 | $21.63 |
| Diluted EPS | $8.79 | $11.18 | $7.97 | $20.87 | $10.40 | $24.80 | $31.42 | $21.58 |
| Basic Shares Outstanding | 146.50M | 145.60M | 144.70M | 145.30M | 149.10M | 160.90M | 187.10M | 204.90M |
| Diluted Shares Outstanding | 147.10M | 145.90M | 145.60M | 146.00M | 149.60M | 161.30M | 187.40M | 205.30M |
| Period | Consensus EPS | Low | High | Estimates | Revisions |
|---|---|---|---|---|---|
| Dec 2026 | $12.50 | $12.00 | $13.47 | 10 | ↑0 ↓5 |
| Dec 2027 | $16.39 | $11.29 | $19.29 | 21 | ↑3 ↓7 |
| Dec 2028 | $18.09 | $15.25 | $22.28 | 16 | ↑3 ↓1 |
| Dec 2029 | $19.19 | $16.31 | $23.58 | 12 | ↑0 ↓2 |
